Table 4.
Association between region and the prevalence of metastases in breast cancer patients (multivariable logistic regression model)
| Region | Stage IV breast cancer patients | Stage IV breast cancer patients with positive HR status | Stage IV breast cancer patients with negative HR status | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Bone | ||||||
| Europe | Reference | Reference | Reference | |||
| Asia | 0.71 (0.65–0.78) | < 0.001 | 0.56 (0.38–0.82) | 0.003 | 0.60 (0.32–1.12) | 0.109 |
| Latin America | 1.08 (0.98–1.19) | 0.140 | 0.99 (0.73–1.35) | 0.945 | 0.44 (0.16–1.21) | 0.113 |
| Lung | ||||||
| Europe | Reference | Reference | Reference | |||
| Asia | 1.45 (1.33–1.59) | < 0.001 | 1.76 (1.59–1.96) | < 0.001 | 0.99 (0.84–1.15) | 0.848 |
| Latin America | 1.32 (1.19–1.45) | 0.001 | 1.27 (1.13–1.42) | < 0001 | 1.46 (1.21–1.76) | < 0.001 |
| Skin | ||||||
| Europe | Reference | Reference | Reference | |||
| Asia | 0.73 (0.58–0.91) | 0.005 | 0.65 (0.49–0.85) | 0.003 | 0.94 (0.66–1.36) | 0.754 |
| Latin America | 1.17 (0.95–1.43) | 0.137 | 1.04 (0.82–1.32) | 0.727 | 1.60 (1.10–2.34) | 0.015 |
| Liver | ||||||
| Europe | Reference | Reference | Reference | |||
| Asia | 0.94 (0.86–1.03) | 0.193 | 1.02 (0.91–1.14) | 0.751 | 0.81 (0.69–0.94) | 0.006 |
| Latin America | 0.96 (0.86–1.06) | 0.371 | 0.97 (0.86–1.10) | 0.662 | 0.91 (0.76–1.10) | 0.342 |
| Brain | ||||||
| Europe | Reference | Reference | Reference | |||
| Asia | 1.04 (0.84–1.29) | 0.729 | 1.18 (0.90–1.56) | 0.229 | 0.89 (0.64–1.24) | 0.489 |
| Latin America | 0.93 (0.73–1.19) | 0.552 | 0.61 (0.42–0.88) | 0.008 | 1.49 (1.07–2.09) | 0.020 |